A newsletter on toxicology and drug development — how it actually works.

The Nonclinical is a free bi-weekly newsletter for early-career toxicologists, PhD students, and DABT candidates who want to understand nonclinical drug development from the inside out.

Every issue covers:

How study designs actually get made
Species selection and why it matters
GLP requirements and what regulators look for
IND-enabling strategy and the decisions behind it
How safety calls get made in real programs

No textbook theory. Just the stuff that matters when you're actually doing the work.

Written by Dessi McEntee, MS, DABT

— Board-certified toxicologist

— Fractional Head of Toxicology

— Author of Data Is Not Strategy

Here's a sneak peek of The Nonclinical:

“No Major Findings”: The Hidden Risk

"No major findings" is one of the most reassuring phrases in nonclinical development — and one of the most dangerous. It describes what wasn't observed. It doesn't interpret what the study actually resolved. Once that phrase enters the conversation, attention shifts, assumptions harden, and questions stop being asked. This issue unpacks why clean studies require more interpretation, not less.

Dessi McEntee

Here's a sneak peek of The Nonclinical:

“No Major Findings”: The Hidden Risk

QUESTIONS?